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Purpose. To understand the role of polymorphisms in the LEP (rs7799039 and rs2167270) and LEPR (rs1137101 and rs1137100) genes
inDTC susceptibility and their effect on leptin levels.Methods.We studied 153 patients withDTC and 234 controls through TaqMan
SNP Genotyping and ELISA, comparing these data to the clinicopathological data of patients with DTC. Results. Patients with AA
genotype of rs7799039 had higher levels of serum leptin (9.22 ± 0.98 ng/mL) than those with AG genotype (10.07 ± 0.60 ng/mL;
𝑃 = 0.005). Individuals with AG genotype of rs2167270 also produced higher serum leptin levels (10.05 ± 0.59 ng/mL) than the
subjects with GG genotype (9.52 ± 0.79 ng/mL; 𝑃 < 0.05). A multivariate logistic regression adjusted for gender, age, and BMI
showed that the AG genotype of rs7799039 was an independent risk for DTC (OR, 11.689; 𝑃 = 0.0183; 95% CI, 1.516–90.119).
Similarly, AG and GG genotypes of rs1137101 increased the susceptibility to DTC (OR, 3.747; 𝑃 = 0.027; 95% CI, 1.161–12.092 and
OR, 5.437; 𝑃 = 0.013; 95% CI, 1.426–20.729). Conclusions.We demonstrated that rs7799039 and rs2167270 polymorphisms modify
the serum leptin concentrations in patients with DTC. Furthermore, polymorphisms rs7799039 and rs1137101 increase the risk of
DTC development, although they do not correlate with tumor aggressiveness.
1. Introduction
Themechanisms underlying the relationship between cancer
andobesity have not been established andmay vary according
to the primary tumour location [1, 2].These variationsmay be
attributed to the metabolic and endocrine effects that obesity
may exert on the metabolism, hormones, inflammation, and
protein production [3], thus leading to the development and
progression of cancer.
Our group has previously demonstrated that cytokines
produced by adipocytes (adipokines), such as adiponectin,
leptin, and resistin, are differentially expressed in malignant
and benign thyroid nodules, helping to differentiate not only
malignancy but also subtypes of thyroid nodules, which are
difficult to identify using PAAF [4]. Of the three adipokines,
leptin presents as an interesting diagnostic option for thyroid
malignancy; leptin has a 100% accuracy, as well as high
sensitivity and specificity. Additionally, the serum leptin
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levels differed in follicular lesions, which is currently the
primary diagnostic challenge for pathologists, introducing a
fascinating clinical perspective to the diagnosis of thyroid
malignancy using a simple and robust blood test [4].
Physiological mechanisms may influence the synthesis of
leptin and thus lead to variations in the amounts of leptin
associated with the fat mass [5]. Notably, several cytokines,
such as tumour necrosis factor alpha (TNF-𝛼), increase the
expression of leptin through mRNA synthesis [6]. Addition-
ally, recent evidence has indicated that the modulation of
leptin’s gene expression might be related to the presence
of polymorphisms in LEP and LEPR (leptin receptor) gene
[7, 8]. The polymorphisms in these genes have been recently
related to an increased susceptibility to several types of
cancer, such as prostate, breast, gastric, and lung carcinomas
[9–13]. Hence, we hypothesised that polymorphisms in LEP
and LEPR could lead to an increased risk for differentiated
thyroid cancer (DTC), thus establishing the link between the
observed epidemiological increases in both thyroid cancer
and obesity rates.
The objective of the present study was to investigate the
polymorphisms inLEP andLEPR genes in patientswithDTC,
correlating the obtained data with previouslymeasured leptin
serum levels, DTC risk, and clinicopathological features.
2. Subjects and Methods
2.1. Patients. This study was approved by the Research Ethics
Committee of the participating centres. All of the participants
signed the informed consent forms. We investigated 153
patients (130 females, 23males, 40.87±13.80 years) diagnosed
with DTC and 234 healthy controls (204 females, 30 males,
37.61 ± 13.39 years) with no significant differences in gender,
age, and body mass index (BMI). Seventy-four of 153 patients
included in this study had been previously described in
another report and had serum leptin levels measured [4].
The patients were consecutively referred to the Thyroid
Cancer Unit, Division of Endocrinology, Unicamp Teaching
Hospital in Campinas, Sa˜o Paulo, Brazil, and to the Head and
Neck Department of the Barretos Cancer Hospital, Barretos,
Sa˜o Paulo, Brazil, between 2009 and 2011, for thyroid nodule
diagnostic evaluations. They were submitted to interviews,
using a structured in-person questionnaire that allowed the
recollection of information, such as demographic, social,
economic, and xenobiotic exposures, food intake, and pre-
vious disorders. The questionnaire has been used in several
publications by our group in recent years [14–17].
To classify BMI, heightwasmeasuredwith the individuals
standing barefoot on a stadiometer with a centimetre scale.
Weight was measured using a balance with division of 100 g,
with all of the individuals wearing light clothes and no shoes.
BMI was calculated using the formula (weight)/(height)2.
All of the participants were classified using the WHO
recommendation for nutritional status as follows: normal
weight, 18.5–24.99 kg/m2; overweight, ≥25–29.99 kg/m2; and
obese, ≥30 kg/m2 [18]. Underweight patients (<18.49 kg/m2)
were excluded from the study because we could not obtain
underweight controls.
Anatomopathological data, including nodule size,
tumour histological features and image, as well as laboratory
data were retrieved from the patients’ medical records.
All thyroid cancer histological samples were reviewed
for diagnostic confirmation by a thyroid pathologist (J.
Vassallo). Chronic lymphocytic thyroiditis, investigated in
the nonmalignant parenchyma of the contralateral thyroid
lobe, was characterised by extensive lymphocytic infiltration
with lymphoid follicles, scarring, and follicular regenerative
activity in the form of numerous small follicles, frequently
lined by Hurthle cells.
Thyroid cancer patients were monitored using periodic
total body scans and serum TSH and thyroglobulin (Tg)
measurements, according to a standard protocol based on
the AmericanThyroid Association and Latin AmericanThy-
roid Association recommendations [19, 20], which included
X-ray, ultrasonography, computed tomography scans, and
other timely and necessary procedures for detecting distant
metastasis for a period of 18–56 months (40.8 ± 16 months).
The aggressiveness of the cancer at the time of diagnosis
was ascertained using the TNM stage classification system
for differentiated thyroid carcinoma [21]. The patients were
also classified into low, intermediate, and high risk groups,
according to the ATA guidelines [19]. The patients who
presented with suspicious or high serum Tg levels (>2 ng/dL)
underwent intensive imaging procedure.Wedefined tumours
as recurrent and long-distance metastasis according to the
above-mentioned parameters. The patients with thyroid can-
cer were classified as disease-free when they maintained
serum Tg levels <2 ng/dL and exhibited no clinical or image
suspicion of disease for at least 12 consecutive months after
surgery. There were 80 patients (63.5%) who were free of
disease and 46 patients (37.5%) with recurrence. Twenty-
seven patients could not be classified into any of these
two groups and were excluded from any analysis involving
outcome. No patient died of the disease during our follow-
up.
Healthy individuals included in the control group pre-
sented neither history of malignancy in the family nor
familial history of thyroid diseases. These individuals were
blood donors of the Hematology and Hemotherapy Center,
located in the University of Campinas.
2.2. Serum Analysis. The 74 individuals investigated for
serum leptin levels have undergone similar blood collection
procedures, based on the previously described method [22–
24]; that is, 4mL of whole blood was collected in red plastic
tubes that had no anticoagulant factors and contained a gel
with intermediate density between blood cells and serum.
The serum samples were then separated by centrifugation at
3000 rpm for 10min and stored at −20∘C, until analysis could
be performed.We used commercial ELISA assays to quantify
the circulating leptin levels (R&DSystems,Minneapolis,MN,
USA).
2.3. Genotype Analysis. Approximately 4mL of peripheral
blood was collected into EDTA (ethylenediaminetetraacetic
acid) coated tubes. Genomic DNA was extracted from
leucocytes separated from whole blood, using a standard
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Table 1: Comparisons of different histopathological types according to their leptin serum expression.
Analysed groups Leptin 𝑃
Malignant versus benign 9.89 ± 0.63 versus 1.92 ± 0.69 <0.001
CPTC versus goiter 9.69 ± 0.89 versus 1.88 ± 0.73 <0.001
CPTC versus FA 9.69 ± 0.89 versus 2.11 ± 0.47 <0.01
CPTC versus FC 9.69 ± 0.89 versus 9.49 ± 0.50 N.S.
FVPTC versus CPTC 10.02 ± 0.57 versus 9.69 ± 0.89 N.S.
FVPTC versus goiter 10.02 ± 0.57 versus 1.88 ± 0.73 <0.001
FVPTC versus FA 10.02 ± 0.57 versus 2.11 ± 0.47 <0.001
FVPTC versus FC 10.02 ± 0.57 versus 9.49 ± 0.50 N.S.
FC versus FA 9.49 ± 0.50 versus 2.11 ± 0.47 <0.001
FC versus goiter 9.49 ± 0.50 versus 1.88 ± 0.73 <0.01
FA versus goiter 2.11 ± 0.47 versus 1.88 ± 0.73 N.S.
CPTC: classic type PTC; FVPTC: follicular variant PTC; FC: follicular carcinoma; AF: follicular adenoma; N.S.: not statistically significant.
protocol, which includes leucocyte lysis, SDS treatment,
phenol-chloroform extraction, and ethanol precipitation.
The DNA samples were genotyped for LEP (rs7799039
and rs2167270) and LEPR (rs1137101 and rs1137100) genes
using TaqMan SNP genotyping assays (C 1328079 10,
C 15966471 20, C 8722581 10, and C 518168 20, resp.)
(Applied Biosystems, CA, USA) in the 7500 Real Time PCR
System (Applied Biosystems, CA, USA). The reactions were
carried out using a 25 𝜇L total volume containing 20 ng
of sample DNA, 12.5 𝜇L of TaqMan universal PCR Master
Mix, 0,625 𝜇L of TaqMan assay, and 8.875𝜇L of milli-Q
water. The reactions were then analysed using the allelic
discrimination endpoint analysis of the sequence detection
software package, Sequence Detection Software (SDS) Version
1.3 (Applied Biosystems). These SNPs were selected because
previous studies showed that they were associated with other
cancers, obesity-related diseases, and leptin expression [9,
25–30].
2.4. Statistical Analysis. The statistical analysis was con-
ducted using the SAS statistical software (Statistical Analysis
System, version 8.1, 1999-2000, Cary, NC, USA). Associations
were assessed using 2 × 2 or 2 × 𝑛 contingency table analyses,
and 𝜒2 or Fisher’s exact test was used to examine homogene-
ity between cases and controls. Kruskal-Wallis and Mann-
Whitney tests were used to compare the mean ages of
patients and controls and to compare the mean serum leptin
expression among genotypes. The odds ratio (OR) and 95%
CI provided the measurements of association strength. The
variables that were significantly associated with DTC using
univariate analysis were analysed using a multiple logistic
regression model for evaluating the effect of all genotypes
and clinical risk factors. To analyse the primary factors
related to the disease-free interval, Cox regression analysis
was performed.All of the tests were conducted at the𝑃 < 0.05
significance level.
3. Results
Themajority (82%) of the patients were females, aged 14 years
to 76 years (41.02 ± 15.54 years) and 87% had an anticipated
diagnosis of papillary thyroid carcinoma (PTC).Multifocality
was observed in 55% of the patients and 59% presented
invasion of the capsule. Stage I (40%) and stage II (35%) were
more frequent, although at the reference hospitals involved in
this study there were a large proportion of stage III (10%) and
stage IV (15%) cases. In fact, 37 patients presented metastasis
at the time of diagnosis.Moreover, concurrent thyroiditis was
diagnosed in 48% of the patients. The majority (63.5%) of
the patients evolved free of disease after a 9-year follow-up
period (101.5 ± 57.6 months). However, 46 patients (36.5%)
presented recurrence or metastasis during the follow-up.
3.1. Serum Analysis. As we have previously described, leptin
presented outstanding accuracy in the diagnosis of thyroid
nodule malignancy [4]. All of the parameters considered
for a diagnostic test were noticeable. For a cut-off point of
7.24 ng/mL, the serum levels of leptin differentiated all of the
malignant lesions from the benign lesions, with sensitivity,
specificity, and positive predictive value and negative predic-
tive value of 100% (𝑃 = 1 × 10−6). Additionally, leptin serum
levels differentiated the follicular variant of papillary thyroid
cancer (FVPTC) from the follicular adenomas (FA) (𝑃 <
0.001) and from goiters (𝑃 < 0.001). They also distinguished
FA from the follicular carcinomas (FTCs) (𝑃 < 0.001)
and from the classic PTC (CPTC) (𝑃 < 0.001) [4]. These
results are shown inTable 1. Although leptinwas differentially
expressed among thyroid lesions, it did not correlate with any
clinicopathological feature (Table 2).
3.2. Genotyping Analysis. A multivariate logistic regression
adjusted for gender, age, smoking, and BMI showed that
the AG genotype of LEP rs7799039 was an independent risk
for DTC (OR, 11.689; 𝑃 = 0.0183; 95% CI, 1.516–90.119).
Similarly, AG and GG genotypes of LEPR rs1137101 repre-
sented independent risks for DTC (OR, 3.747;𝑃 = 0.027; 95%
CI, 1.161 to 12.092, and OR, 5.437; 𝑃 = 0.013; 95% CI, 1.426 to
20.729, resp.).
The AA genotype of LEPR rs1137100 was more frequent
among patients with FTC (93.8%) than among patients with
PTC (60.2%; chi-square = 8.219, 𝑃 = 0.016). There was no
association between the genotypes and the presence of
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Table 3: Mean and median leptin serum expressions according to the genotypes of the studied SNPs.
Gene-rs (𝑁)
Mean
expression
(ng/mL)
Standard deviation Median (ng/mL) 𝑃
LEP rs7799039 (78) 0.012∗
AA (12) 9.22 0.98 9.37 <0.05#
AG (36) 10.07 0.60 10.07 >0.05$
GG (30) 9.75 0.56 9.84 >0.05$
LEP rs2167270 (78) 0.018∗
AA (8) 9.89 0.49 9.80 >0.05#
AG (38) 10.05 0.59 10.00 <0.05&
GG (32) 9.52 0.79 9.58 >0.05$
LEPR rs1137101 (78) N.S.
AA (20) 9.75 0.59 9.83
AG (40) 9.89 0.76 9.85
GG (18) 9.74 0.74 9.96
LEPR rs1137100 (73) N.S.
AA (48) 9.88 0.76 9.96
AG (20) 9.77 0.72 9.84
GG (5) 9.76 0.42 9.86
∗AA × AG × GG; #AA × AG; &AG × GG; $AA × GG; N.S.: nonsignificant.
features that could be related to aggressiveness, such asmulti-
focality, invasion of the capsule, and concomitant thyroiditis.
However, the GG genotype of rs2167270 of LEP gene was
more frequent among the patients diagnosed with the less
advanced stage (I and II, 46.2%) than among the patients
diagnosed with the more advanced stage (III and IV, 22.7%,
chi-square = 6,311; 𝑃 = 0.043), as shown in Table 2.
The survival analysis showed no association between
the disease-free interval and gender, ethnicity, smoking,
multifocality, invasion of capsule, and thyroiditis. None of the
genotypes investigated was associated with the disease-free
period.
3.3. Leptin Concentrations versus Genotypic Profile. LEPR
polymorphisms did not correlate with the serum concentra-
tions of leptin as shown in Table 3. In contrast, we observed
a good correlation between LEP gene genotype and serum
leptin levels. The patients who presented the AA genotype
of rs7799039 in LEP gene had lower serum levels of leptin
(9.22±0.98 ng/mL) than those with the AG genotype (10.07±
0.60 ng/mL; 𝑃 = 0.005). The individuals with the AG geno-
type of SNP rs2167270 also produced higher serum leptin
levels (10.05 ± 0.59 ng/mL) than the subjects with the GG
genotype (9.52 ± 0.79 ng/mL; 𝑃 < 0.05).
4. Discussion
It is recognised that leptin is a component of a series of
important thyroid cell processes, including the regulation of
TSH expression [31] and the development of autoimmunity
[32, 33], and that serum leptin levels may be related to the
presence of insulin resistance in hypothyroidism [34] and to
other diseases that may be associated with thyroid disorders,
such as obesity and insulin resistance. However, the present
study is the first to investigate the occurrence of genetic
changes in LEP and LEPR genes in DTC, which might be a
likely link between obesity and thyroid cancer.
To the best of our knowledge, we demonstrate for the
first time that polymorphisms in LEP (rs7799039) and LEPR
(rs1137101) may increase the risk of DTC development.
The SNP rs7799039 in LEP gene has been associated with
an increase in BMI, overweight, and even with variations
in serum leptin concentration [27, 35, 36]. A meta-analysis
that included 5 articles related to this SNP and colorectal
carcinoma risk and 3 studies related to prostate cancer
susceptibility concluded that this alteration in LEP may
increase the risk for prostate cancer but not for colorectal
carcinoma [9]. Additionally, several authors have attempted
unsuccessfully to establish a relationship between this poly-
morphism and breast cancer [37].
We demonstrated that serum leptin concentration varies
according to specific inherited genotypes. Hoffsted et al. [38]
showed that individuals with the AA genotype of rs7799039
had higher serum leptin concentrations than the AG or GG
genotypes carriers. Our data confirmed significant differ-
ences of this cytokine depending on the genotype, although
with more discrete variations. Because this SNP is located
in the promoter region, this polymorphism may affect gene
expression at a transcriptional level, leading to more or less
leptin production. These findings may also explain the fact
that there was no correlation between serum leptin and BMI
in our population, allowing us to hypothesise that changes
in this gene may be even more important than the effects of
obesity in the secretion of this hormone.
Regarding SNP rs1137101, which we demonstrated to
be related to an increased risk for DTC, reports in the
6 International Journal of Endocrinology
literature have shown that variants of LEPR are related
to the following: increased BMI, insulin resistance, and
correlationwithHOMA-IR (an index used for the assessment
of insulin resistance), metabolic syndrome, increased fat
mass and adipocytes, increased waist circumference, obesity,
development of type 2 diabetes mellitus (T2DM), and serum
concentrations of circulating leptin [39–52]. This polymor-
phism has been associated with breast, prostate, and lung
cancers and polycystic ovary syndrome [53–59].
We described the relationship of rs2167270 of LEP with
different serum levels of leptin. Friedlander et al. [60] corre-
lated LEP rs2167270 genotypes with increased bodymass and
waist circumference in women, and Jiang et al. [27] reported
that this polymorphism is associated with increased BMI.
The AA genotype of rs2167270 was associated with a lower
risk of colorectal cancer [25]. Although the variations in LEP
may alter the amount of leptin produced, no relationship was
found between rs2167270 and increased risk for DTC.
In conclusion, we demonstrated that rs7799039 and
rs2167270 polymorphisms of LEP modified the serum con-
centrations of leptin in patients with DTC. Furthermore,
the polymorphisms rs7799039 in LEP and rs1137101 in LEPR
increased the risk for developing DTC, although they did not
appear to correlate with tumour aggressiveness.
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